Core Insights - Dyadic Applied BioSolutions and Fermbox Bio have launched the first commercial product, animal-origin-free Recombinant DNase I, marking a significant step in their collaboration and commercial product expansion [1][3][4] Group 1: Product Launch and Development - Recombinant DNase I (RNase-free) is produced using Dyadic's high-yield fungal microbial expression platforms and Fermbox Bio's biomanufacturing capabilities, currently available in research grade with a cGMP-grade version in development [2][6] - The enzyme is crucial for nucleic-acid clean-up and sample preparation, supporting RNA integrity in various applications including biotechnology and molecular diagnostics [3][5] - This product is the first in a series of recombinant enzymes and proteins planned for commercialization throughout 2026 [4] Group 2: Future Product Pipeline - Planned pipeline products include recombinant α-lactalbumin, recombinant transferrin, recombinant human FGF-2, and recombinant human lactoferrin, targeting high-demand segments in cell culture media and molecular biology reagents [5] - These products will support applications in cell and gene therapy, vaccine manufacturing, and advanced biologics development [5] Group 3: Collaboration Framework - Under the collaboration, Dyadic provides its expression platforms and production strains, while Fermbox Bio focuses on downstream process development and manufacturing [6] - The companies aim for global commercialization to serve research and biomanufacturing customers [6] Group 4: Company Background - Dyadic Applied BioSolutions specializes in producing recombinant proteins for life sciences, food, and bio-industrial markets, utilizing proprietary microbial platforms [7] - Fermbox Bio develops sustainable bio-based products through precision fermentation and advanced biotechnology [8]